A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain

Inclusion criteria

• ✓. Patients with a definitive diagnosis of neuropathic pain, including but not limited to painful diabetic peripheral neuropathy, trigeminal neuralgia, and post-stroke pain, aged 18-65 years old (regardless of gender), with:
• ✓. Regularised treatment with conventional medical therapy (including, but not limited to, medication, physiotherapy, cognitive therapy, nerve blocks and other non-invasive or minimally invasive treatments) for at least 3 months with no symptomatic relief or emergence of tolerance, as assessed by the investigator
• ✓. Pharmacological treatment means a full course of treatment with at least two first-line medications, as assessed by the investigator
• ✓. Mean visual analogue scale (VAS) value ≥4 cm and/or mean numerical rating scale (NRS) value ≥4 points within one week of baseline at enrolment
• ✓. Subjects who have had a stable analgesic regimen for at least 30 days prior to the intensity of pain described in Inclusion Criterion 2 and agree not to arbitrarily change the type and dose of medication that they are currently taking until the end of the period of assessment of the effectiveness of this trial, as assessed by the investigator
• ✓. Subjects volunteered to participate in the trial and gave fully informed consent to sign an informed consent form
• ✓. Have stable neurological status as assessed by the researcher through motor, sensory and reflex functions
• ✓. Subjects are considered reliable and able to comply with the trial protocol (e.g., able to understand and complete relevant scales), visit protocols, and medication administration, according to the investigator's judgement

Exclusion criteria